# US 8,647,865 B2 · Promiscuous PAP CD4 T cell epitopes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,647,865 B2
- Document ID: US8647865B2
- Status: Granted
- Kind: B2
- Application number: 13/734,560
- Filed: 2013-01-04
- Published: 2013-08-08
- Granted: 2014-02-11
- Earliest claimed: 2006-08-11
- Assignees: Dendreon Corporation
- Applicants: Dendreon Corporation
- Inventors: Jami B. Wollan; Lori A. Jones
- Web page: https://patentgrep.com/patent/US8647865B2

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61P 13/08: of the prostate
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF
- C12N 9/16: acting on ester bonds (3.1)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to the discovery of novel T cell epitopes of the human prostatic acid phosphatase (PAP) protein that is promiscuous for at least 15 different HLA-DR alleles. The invention also relates to compositions that contain one of the novel epitopes or a fusion peptide of such an epitope and a heterologous polypeptide. Further disclosed herein is the use of the epitopes or their fusion peptides, and compositions containing the epitopes or their fusion peptides.

## Claims

### Claim 1

An isolated nucleic acid encoding a fusion polypeptide consisting of (1) a peptide consisting of 15 to 18 amino acids and comprising the amino acid sequence of SEQ ID NO:1, fused to (2) a heterologous peptide via a peptide bond.

### Claim 2 (depends on 1)

The nucleic acid of claim 1, wherein the peptide in (1) consists of the amino acid sequence of SEQ ID NO:1.

### Claim 3 (depends on 1)

The nucleic acid of claim 1, wherein the heterologous peptide is a granulocyte-macrophage colony-stimulating factor (GM-CSF).

### Claim 4 (depends on 1)

The nucleic acid of claim 1, wherein the fusion polypeptide is the peptide of SEQ ID NO:1 fused to a granulocyte-macrophage colony-stimulating factor (GM-CSF) via a peptide bond.

### Claim 5 (depends on 1)

An expression cassette comprising the nucleic acid of claim 1 and directing the expression of a fusion polypeptide consisting of (1) a peptide consisting of 15 to 18 amino acids and comprising the amino acid sequence of SEQ ID NO:1, fused to (2) a heterologous peptide via a peptide bond.

### Claim 6 (depends on 5)

The expression cassette of claim 5, which is a recombinant viral vector.

### Claim 7 (depends on 5)

The expression cassette of claim 5, wherein the peptide in (1) consists of the amino acid sequence of SEQ ID NO:1.

### Claim 8 (depends on 5)

The expression cassette of claim 5, wherein the heterologous peptide is a granulocyte-macrophage colony-stimulating factor (GM-CSF).

### Claim 9 (depends on 5)

The expression cassette of claim 5, which directs the expression of a fusion polypeptide consisting of (1) a peptide consisting of the amino acid sequence of SEQ ID NO:1, fused to (2) a granulocyte-macrophage colony-stimulating factor (GM-CSF) via a peptide bond.

### Claim 10 (depends on 5)

A host cell comprising the expression cassette of claim 5.